Researcher:
Karabıyık, Göktuğ

Profile Picture
ORCID

Job Title

PhD Student

First Name

Göktuğ

Last Name

Karabıyık

Name

Name Variants

Karabıyık, Göktuğ

Email Address

Birth Date

Filters

2021 - 20222

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.14b19d21-3fb8-43f9-a8b8-2f888ba5a45f

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
    (Nature Portfolio, 2022) Philpott, Martin; Cribbs, Adam P.; Kung, Sonia H.Y; Bayram, Özlem Yedier; Gökbayrak, Bengül; Kayabölen, Alişan; Aksu, Ali Cenk; Cavga, Ayşe Derya; Cingöz, Ahmet; Kala, Ezgi Yağmur; Karabıyık, Göktuğ; Esin, Beril; Morova, Tunç; Uyulur, Fırat; Önder, Tuğba Bağcı; Syed, Hamzah; Lack, Nathan Alan; Önder, Tamer Tevfik; PhD Student; Faculty Member; Faculty Member; Faculty Member; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); School of Medicine; Graduate School of Health Sciences; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 184359; 318138; 120842; 42946
    Dysregulation of the epigenome due to alterations in chromatin modifier proteins commonly contribute to malignant transformation. To interrogate the roles of epigenetic modifiers in cancer cells, we generated an epigenome-wide CRISPR-Cas9 knockout library (EPIKOL) that targets a wide-range of epigenetic modifiers and their cofactors. We conducted eight screens in two different cancer types and showed that EPIKOL performs with high efficiency in terms of sgRNA distribution and depletion of essential genes. We discovered novel epigenetic modifiers that regulate triple-negative breast cancer (TNBC) and prostate cancer cell fitness. We confirmed the growth-regulatory functions of individual candidates, including SS18L2 and members of the NSL complex (KANSL2, KANSL3, KAT8) in TNBC cells. Overall, we show that EPIKOL, a focused sgRNA library targeting similar to 800 genes, can reveal epigenetic modifiers that are essential for cancer cell fitness under in vitro and in vivo conditions and enable the identification of novel anti-cancer targets. Due to its comprehensive epigenome-wide targets and relatively high number of sgRNAs per gene, EPIKOL will facilitate studies examining functional roles of epigenetic modifiers in a wide range of contexts, such as screens in primary cells, patient-derived xenografts as well as in vivo models.
  • Thumbnail Image
    PublicationOpen Access
    Milestones of CRISPR/Cas9 system, promises and roadblocks
    (Elsevier, 2021) Karabıyık, Göktuğ; Researcher; Graduate School of Health Sciences
    In this issue of Cancer Treatment and Research Communications, Sarkar et al. describe CRISPR/Cas9-based gene-editing from its discovery to current views. Originally a bacterial adaptive immune system, CRISPR/Cas9 was adapted to mammalian cells as a tool to perform a wide range of actions given its capability of accurately targeting specific DNA loci. While the CRISPR/Cas9 system is readily used in laboratories as a research tool for a few years now, the first clinical trials have recently started utilizing this system in translational medicine. Although several obstacles have been resolved related to the usage of CRISPR/Cas9 on mammalian cells, the scientific community is facing new challenges with this technology.